VerifyMe Inc. specializes in internet security, anti-counterfeiting, and product authentication. With cyberfraud becoming a bigger and bigger issue, their services will only get more valuable. With a market cap of 31M, this stock is somewhat volatile, but the company is fairly stable and they should deliver large gains in the long run. I think shares could easily...
Avinger Inc. shares hit support today and saw decent growth after hours, suggesting that they could bounce higher. The MACD indicator just crossed, which is always a good sign. The RSI indicator looks bullish as well. I am expecting a bounce similar to the one we experienced on the 18th, probably not as big, but it is highly likely it will at least break $2. Good...
Nio has been tanking lately, but this shouldn't be a reason for long-term investors to sell. Don't get scared, Nio will go up eventually. This mini tech crash should wear off soon.
Luminar Tech shares broke the bottom of the wedge they have been forming today, falling over 7%. In doing this, they found support. They also are resting on the bottom of the RSI, another bullish sign. Expect a bounce soon as they rise back up into the wedge. I still think a breakout is coming, maybe around the 5th or so. Good Luck!
LMND has hit the support zone again, so I think it could swing back up to $170 soon. This stock is also likely to break out in the next month (breakout wedge forming), so now is a great entry point if you are watching for that. LMND is also a great long-term, I think it could push all the way to $300 this year. Good Luck!
This stock grew from 30 cents to $10 in the past months, and each time it broke out it formed some sort of wedge formation. It now is forming another wedge, which could mean that it could break out again. I am doubtful it will go past $17 again, but I think it may see that zone again soon. I am holding right now, and I am planning on selling in two weeks or...
Nio Inc shares saw massive growth in 2020, starting out at around $3 in January and pushing all the way to $50 in December, almost 2,000%. I think this "Chinese Tesla" is merely at the beginning of a massive uptrend. EV stocks are already some of the best-performing stocks on the market right now, and Nio is definitely the best of them in my opinion. The Chinese...
Genetics could be the technology of tomorrow. Using genetic sequencing, scientists have been able to make new medications for diseases that work very effectively. They have also been able to use genetics to study how certain diseases impact people. This stock has the potential to rise much more. Target the $130-$150 zone.
Aprea Therapeutics dropped over 70% in December, and now that it shows strong upside, this stock is pure gold. It is riding around 6.67 right now, and I think that it has the potential to reach up to 30$ this year. I will let you know if you should sell. I have already entered here, but you could wait to buy until it drops into the lower half of the Linear...
After losing most of its value, OVID sort of did nothing for the past month. However, recently it showed strong upside which makes me think it could bounce back eventually. If you like this idea, take a look at my idea on APRE and also look at UBX and how they bounced back. Target the $6 zone.
What if I told you you could slow your aging dramatically by simply taking a pill? UBX has been working on this for a very long time, and they have showed promise in their trials. The risk could be somewhat high, but you could be looking at a potential 20,000% upside if they are successful.
SiTime Corporation is still producing strong products that help with technologies across the board. They are still a stellar long term investment, but as you can see in the chart, SITM shares have capped off at the top of the linear regression channel. Look to pull out Monday and re enter once they fall below 110.
Clean Energy has changed the way the world fuels its vehicles. Natural Gas is becoming more available to countries around the world, and many are already using it for their public transportation vehicles. Look to target the $14-$15 zone. There is a chance that CLNE will fall next week, but most likely the uptrend will continue.
Zymeworks is releasing a new drug, ZW25, to treat HER2-expressing Gastroesophageal Adenocarcinoma. The phase one trials for this drug done, and the data for the trials will be released on January 15, 2021. For optimal gains, buy a week in advance and sell the day of the data release. Again, the data will be released 11:30-12:15 EST on January 15, 2021 . Like and...
